# ProAxsis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proaxsis

- Industry: Healthcare
- Headquarters: Belfast, UK
- Website: www.proaxsis.com
- Total disclosed funding: $0.3M
- Latest round: Seed (Feb 23, 2014)
- Investors on record: 2

## About

Based in Belfast, UK, and co-founded by Brian Walker and Lorraine Martin in 2013, ProAxsis Ltd operates as a diagnostic company offering diagnostic assay kits for the measurement of active protease biomarkers of disease. In April 2024, the firm raised GBP 1.47 million in venture funding led by investor EMV Capital. The firm as of April 2024, has distributors across the UK, the US, Germany, and Singapore, and is led by its founders, chairman, Alan Markey, and Head of operations, Louise Ryan Murphy.

ProAxsis develops and supplies diagnostic tests that detect active protease biomarkers, offering a crucial opportunity for early intervention in diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Bronchiectasis, and Alpha-1 Anti-trypsin Deficiency (A1ATD), by utilizing its ProteaseTag® Technology. ProAxsis' assays, based on its patented ProteaseTag® molecules, enable rapid and specific detection of protease activity, paving the way for personalized treatment strategies and improved patient outcomes. Their product range includes NEATstik®, ProteaseTag® Active Neutrophil Elastase Immunoassay, ProteaseTag® Active Proteinase 3 Immunoassay, and K-Postn Immunoassay. Additionally, the firm also offers a range of clinical support and R&D services, including clinical trial support, assay development, and customized research projects.

## Funding rounds

- Seed, Feb 23, 2014, $0.3M — Qubis, Netscientific

## Investors

- Qubis (https://capitalatlas.ai/funds/qubis) — Seed
- Netscientific — Seed